About
Mass cytometry is a hybrid technique combining flow cytometry and mass spectrometry. It uses antibodies conjugated with heavy metals rather than fluorochromes to label cells expressing proteins of interest, followed by time-of-flight (TOF) mass spectrometry for detection. The advantages include significantly enhanced multiplexing without the need for compensation between channels.
The Single Cell Imaging and Mass Cytometry Analysis Platform (SCIMAP) provides researchers with access to the latest and most advanced technologies in spatial biology and single-cell analysis. Our state-of-the-art tools are designed to meet the diverse and evolving needs of the research community, enabling groundbreaking discoveries in a wide range of fields, including cancer biology, neuroscience, immunology, and developmental biology. Below, you’ll find a list of the key technologies we offer, each equipped with specialized capabilities to support your research goals.
Leadership Team
Scientific Director
Logan Walsh, PhD
Platform Manager
Yuhong Wei, PhD
Tags: Tags: Mass Cytometry Core Facility, McGill Goodman Cancer Institute, GCI Fluidigm, CyTOF, Helios, Hyperion, single-cell mass cytometry, imaging mass cytometry, multiplex immunostaining
